Blog
RSS FeedPosted by Michael Wonder on 28 Oct 2022
Health Canada approves Rebinyn (coagulation factor IX (recombinant), pegylated) for the treatment of routine prophylaxis to prevent or reduce frequency of bleeding episodes in children with haemophilia B
27 October 2022 - Expanded indication for Rebinyn will continue to support Canadian paediatric patients living with haemophilia B. ...
Posted by Michael Wonder on 27 Oct 2022
PMPRB finds ultra-rare drug Procysbi is excessively priced
26 October 2022 - On 1 September 2022, a Panel of the Patented Medicine Prices Review Board issued a decision that ...
Posted by Michael Wonder on 27 Oct 2022
Health Canada approves Kerendia (finerenone) as an adjunct to standard of care therapy in adults with chronic kidney disease and type 2 diabetes
26 October 2022 - The approval is based on the results of the Phase 3 FIDELIO-DKD and FIGARO-DKD trial investigating the ...
Posted by Michael Wonder on 25 Oct 2022
A perspective on life cycle health technology assessment and real world evidence for precision oncology in Canada
25 October 2022 - Health technology assessment can be used to make healthcare systems more equitable and efficient. Advances in precision ...
Posted by Michael Wonder on 24 Oct 2022
Saskatchewan becomes sixth Canadian province to implement a biosimilar switching policy
21 October 2022 - Saskatchewan joined five provinces and one territory in implementing a biosimilar switching policy, allowing for reference ...
Posted by Michael Wonder on 20 Oct 2022
AbbVie's Skyrizi (risankizumab) receives Health Canada approval as the first and only specific interleukin-23 to treat moderately to severely active Crohn's disease in adults
20 October 2022 - Third approved indication for Skyrizi (rizankizumab) is supported by safety and efficacy data from two induction and ...
Posted by Michael Wonder on 19 Oct 2022
Evusheld receives Health Canada approval for treatment of COVID-19
18 October 2022 - Evusheld significantly reduced risk of severe COVID-19 or death in TACKLE Phase 3 treatment trial. ...
Posted by Michael Wonder on 17 Oct 2022
Gene therapy Luxturna now reimbursed in Quebec for people with previously untreatable inherited vision loss
17 October 2022 - Quebec leads the way as the first province to reimburse Luxturna (voretigene neparvovec) for previously untreatable inherited ...
Posted by Michael Wonder on 14 Oct 2022
Health Canada approves Illuccix for prostate cancer imaging
13 October 2022 - Telix Pharmaceuticals announces that Health Canada has approved Illuccix [kit for the preparation of gallium (Ga 68) ...
Posted by Michael Wonder on 13 Oct 2022
Health Canada approves Keytruda (pembrolizumab) as monotherapy for the adjuvant treatment of adults with renal cell carcinoma (RCC) at intermediate-high or high risk of recurrence following nephrectomy or following nephrectomy and resection of metastatic lesions
12 October 2022 - Approval based on data from the Phase 3 KEYNOTE-564 trial. ...
Posted by Michael Wonder on 12 Oct 2022
Medical industry advocates urge Ontario to offer cheaper versions of prescription medications
11 October 2022 - Medical industry advocates are urging the Ontario government to offer cheaper versions of certain prescription medications ...
Posted by Michael Wonder on 11 Oct 2022
Trying to survive: To access lifesaving drugs, young cancer patients face huge hurdles
10 October 2022 - Four years ago, Ontarian Rebecca Grundy got a nightmare diagnosis that sent her into a blind ...
Posted by Michael Wonder on 10 Oct 2022
Federal drug price watchdog consulting public on proposed changes to its pricing guidelines
7 October 2022 - The PMPRB's guidelines explain how its staff monitor and review patented medicine prices to ensure they are ...
Posted by Michael Wonder on 08 Oct 2022
Health Canada authorises COVID-19 vaccine booster targeting the Omicron BA.4/BA.5 sub-variants
7 October 2022 - Today, Health Canada authorised a second bivalent COVID-19 vaccine booster. ...
Posted by Michael Wonder on 06 Oct 2022
Santen announces Health Canada approval for Cationorm Plus to relieve the symptoms of dry eye and ocular allergy
6 October 2022 - Santen Canada today announced the approval of Cationorm Plus by Health Canada. ...